

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
31 July 2003 (31.07.2003)

PCT

(10) International Publication Number
WO 03/061475 A1


- (51) International Patent Classification⁷: A61B 5/145, G01N 7/10 (74) Common Representative: DANFOSS A/S; DK-6430 Nordborg (DK).
- (21) International Application Number: PCT/DK03/00036 (81) Designated States (*national*): AM, AT, AU, BA, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HR, HU, IL, IN, IS, JP, KR, KZ, LT, LU, LV, MD, MK, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SK, TR, UA, US, UZ, VN, YU, ZA.
- (22) International Filing Date: 21 January 2003 (21.01.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: PA 2002 00120 23 January 2002 (23.01.2002) DK (84) Designated States (*regional*): Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR).
- (71) Applicant (*for all designated States except US*): DANFOSS A/S [DK/DK]; DK-6430 Nordborg (DK).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): DIRAC, Holger [DK/DK]; Kirsebærlunden 22, DK-3460 Birkerød (DK). SCHWEITZ, Kasper, Oktavio [DK/DK]; Slotshusene 1, 1., Lejl. 13, DK-3400 Hillerød (DK).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHOD AND DEVICE FOR MONITORING ANALYTE CONCENTRATION BY USE OF DIFFERENTIAL OSMOTIC PRESSURE MEASUREMENT



(57) Abstract: A method is provided for the determination of the concentration of compounds in body tissue and fluids. The method utilizes two compartments containing reference solutions, which are separated from the sample by two different semi-permeable membranes, in a serial manner, whereby a difference in osmotic pressure occurs in the two compartments due to compounds, which can permeate one of the membranes, but not the other. The difference in osmotic pressure reflects the concentration of these compounds. The method is especially suited for analysis of the concentration of glucose in blood or tissue of diabetic patients, where a device is implanted underneath the skin of the patient and where the method is carried out by using the implanted device.

THIS PAGE BLANK (00)

- 1 -

Method and device for monitoring analyte concentration by
5 use of differential osmotic pressure measurement

This invention relates to biological sensors, more specifically to implantable sensors for monitoring species
10 such as glucose, in a living creature, for example, in the human or animal body. Further specifically, but not exclusively, this invention relates to biological sensors for the detection of glucose in blood or tissue of a diabetic patient.

15 Diabetic patients can improve their life quality expectancy by maintaining their blood glucose concentration close to the natural level of a healthy person. To achieve this natural concentration, diabetes
20 patients must frequently measure their glucose concentration, and adjust their insulin dosing in accordance with the measured concentration. Usually, a blood sample is obtained for measurement of blood glucose concentration, and there are a number of different glucose
25 test kits on the market based on measurement on blood samples. The disadvantage of these test kits is the need to take a blood sample, which must be collected from a suitable place on the body.

30 Self-monitoring devices, based on capillary blood glucose, are practical but still require repeated and frequent skin punctures, which is inconvenient for the patient, and requires certain hygienic precautions.

- 2 -

Biological sensors in the form of implantable devices are also known in the art and include electrochemical devices and optical devices based on the creation of an electrical or optical signal by the consumption of the compound
5 detected by the analysis. An example is US 6,011,984, which discloses methods utilising an amplification component. The sensitivity and the responsivity of such devices are influenced by the formation of a bio film, for example, by fibrous encapsulation of the device, which
10 reduces the transport rate of the compound to the sensor. Depending on the specific sensor, other mechanisms which cause deterioration of the sensor performance of implanted devices, may also be present, for example, membrane delamination and degradation, enzyme degradation and
15 electrode passivation.

US 5,337,747 discloses an implantable device comprising two measurement chambers each of which comprises an internal measurement chamber isolated from its
20 surroundings by a glucose-impermeable membrane for the first measurement chamber, and by a glucose-permeable membrane which is impermeable to molecules larger than glucose for the second measurement chamber. Each measurement chamber is connected to a pressure sensor and
25 linked to an electronic system provided for informing the environment outside the organism of the value of the pressure measured in each of the two measurement chambers. The pressure difference between the two measurement chambers is interpreted as the osmotic pressure, and this
30 pressure will correspond to a specific level of glucose.

However, the two chambers that constitute the implantable device of US 5,337,747 are in contact with the surroundings at two different locations due to their side-
35 by-side arrangement. This might result in significant

- 3 -

detection errors in cases where the conditions (level of glucose, bio fouling tendency etc.) are different at the two locations. Another problem is the possibly increased tendency for bio fouling of the glucose-impermeable membrane as compared to the glucose-permeable membrane. This increased tendency for bio fouling will change the transport characteristics of the glucose-impermeable membrane and, thus, increase the need for frequent re-calibration of the device, or replacement of the device.

10

It is an object of this invention to overcome the problems with inhomogeneity, and to reduce the rate of bio fouling of the glucose-impermeable membrane.

15 As would be obvious to those skilled in the art, the measurement principle disclosed with this invention is not limited to implanted devices in diabetic patients for measuring glucose concentration, but could be used in many other applications. The basic idea is used for measuring
20 species in locations which are difficult to access, and where the physical- and chemical conditions vary over time. This could be the measurement of the glucose concentration in a bioreactor or in fruit juice etc.

25 The object of this invention is achieved by having two compartments, one of them at least partially defined to the exterior by a first set of barriers permeable for a set of species, the other compartment separated from the first compartment by a second set of barriers permeable
30 only for a subset of the species, only a subset of species that permeates into the first compartment permeates further on into the other compartment. Hereby is achieved that the membranes are connected in a serial manner and, thus, only the glucose-permeable membrane is exposed to
35 bio fouling from species in the surroundings, which cannot

- 4 -

permeate through the first set of barriers. Furthermore, the serial arrangement of the membranes alleviates the problems due to inhomogeneity, as only one compartment is exposed to the surroundings.

5

In one embodiment of the invention, the permeability of the two sets of barriers cause a specific species to be able to permeate into the first compartment, but not into the other compartment. This is achieved in that the first
10 set of barriers is permeable for species up to and including the size of a specific molecule, and the second set of barriers is permeable for species below the size of same specific molecule.

15 In another embodiment of the invention, some of the compartments are filled with a known concentration of species, unable to permeate through the barrier defining the compartment. Hereby is achieved that these compartments work as reference compartments, the
20 determination of the concentration of a specific species occurring through comparison with the reference compartments.

In a specific embodiment of the invention the permeability
25 of the two sets of barriers is such that glucose will be able to permeate into one of the compartments, but not into the other compartment. Hereby a sensor specific for detecting the concentration of glucose in a sample is achieved.

30

In another embodiment of the invention, the pressure difference between the two compartments is detected, so that a value corresponding to the concentration of species permeating into one of the compartments, but not into the
35 other, is obtained.

- 5 -

In a more specific embodiment of the invention a separate pressure sensor detects the pressure exterior to the two compartments. The influence of pressure variations due to conditions external to the device can hereby be compensated.

In another specific embodiment of the invention, the pressure sensing is at least partly formed as a deflection measurement of a flexible compartment, which will increase or decrease in volume when the pressure in the compartment increases or decreases.

In the following the invention is described in detail with reference to the drawings showing:

- Fig. 1: a principal embodiment of the invention showing two compartments, each with a separate barrier.
- Fig. 2: a principal embodiment of a device, where one of the compartments is divided into multiple reference compartments.
- Fig. 3: a principal embodiment of a device having a structure in the form of a disc.
- Fig. 4: an exploded view of the principal device of fig. 3.
- Fig. 5: an exploded view of the principal device of fig. 3, where the barriers are supported by a mechanical structure.
- Fig. 6: Diagram with simulation results for the performance of a device.

Figure 1 shows a sectional view of a device, where two compartments 1 and 2 are stacked on a base plate 3. A perspective view of the same device is shown in figure 3.

- 6 -

The device is implantable into the human body, and is suitable for detecting the glucose level in blood or interstitial fluid.

- 5 Compartment 1 is sealed to the exterior by the ring member 4 and by a barrier 7, and compartment 2 is sealed to the exterior by ring member 5 and base plate 3. A barrier 6 seals the two compartments 1 and 2 from each other.
- 10 Membranes with a specific Molecular Weight Cut Off (MWCO) form each of the barriers 6 and 7. The membrane forming the barrier 6 has an MWCO just below the size of the glucose molecule, and the membrane forming the barrier 7 has an MWCO just above the size of the glucose molecule.
- 15 This means, that only species with the size of the glucose molecule or below will penetrate from the exterior into compartment 1, and that only species with a size below the glucose molecule will penetrate from compartment 1 into compartment 2. The osmotic pressure will then appear over
- 20 the membrane forming the barrier 6, between the two compartments, and two independent pressure sensors 8 and 9 detect the pressure in each compartment. The two pressure sensors 8 and 9 could be substituted with a differential pressure sensor, which is capable of detecting the
- 25 pressure difference between the two compartments 1 and 2. An additional pressure sensor 10 is for the purpose of detecting the surrounding pressure, e.g. the pulse beat and exterior pressure variations can thus be taken into account.
- 30
- Figure 4 shows an exploded view of figure 3, the ring shape of each element 3-7 becoming more visible. The volume of compartment 1 is formed by the internal diameter of the ring shaped element 4 and by the height of element
- 35 4. Similarly, the volume of compartment 2 is formed by the

- 7 -

internal diameter of the ring shaped element 5 and by the height of element 5.

For glucose measurement in a human body, the device of figure 4 could consist of ring shaped elements 4 and 5 with an inner diameter of 500 μ m and a height of 240 μ m. The membrane 7 could be a 500 Da Biotech Cellulose Ester Membrane from Spectrum Laboratories Inc., meaning that the membrane has an MWCO of 500 g/mol. This size will allow the molecule glucose to permeate the membrane, and hence enter the compartment 1. The membrane 6 could be a 100 Da Biotech Cellulose Ester Membrane from Spectrum Laboratories Inc., meaning that the membrane has an MWCO of 100 g/mol. This size will prevent glucose from permeating the membrane.

With dimensions and specifications as described above, the device of figure 4 will perform as indicated in figure 6. Curve 12 shows the glucose concentration in blood or interstitial fluid, varying with the highest rate possible in the human body. Curve 13 indicates the glucose level as given by the device, and curve 14 is the difference between the actual glucose level and the detected glucose level. The difference is within ± 1 mM, which is regarded as an acceptable deviation.

Figure 5 shows a device similar to that of figure 4, only with a rigid element 11 on either side of each membrane. The element 11 must have no influence on the MWCO of the membranes. The purpose of this rigid element is to minimise the deflection of the membrane, due to the pressure difference across it. With less deflection of the membranes, the volume of the compartments will be less dependent of the pressure differences, and less amount of species has to permeate through the membranes to yield the

- 8 -

equilibrium pressure (osmotic pressure), which makes the response time of the device shorter and, thus, the device more accurate. The pressure sensors can be used as previously described. The pressure sensors used in the
5 device shown in figure 4 and 5 might be substituted with a deflection sensor, where the deflection of the membrane then corresponds to the concentration of a given compound.

Figure 2 shows a device in a 3D-view, where the bottom
10 compartment 2 is divided into a number of compartments (2a, 2b and 2c). The top compartment 1 is defined to the exterior by a membrane 7 and to the bottom compartment by a membrane 6, in the same way as described for figure 1. The bottom part itself is divided into a number of
15 compartments, here three, each containing a different and known concentration of a given compound. In the case of detecting the level of glucose in a human body, the compound in each of the compartments 2a-c could be glucose, and the membrane 6 should have an MWCO below the
20 size of the glucose molecule.

As there are different concentrations in each compartment, 2a, 2b and 2c, the differential pressure between compartment 1 and each of 2 will vary from each other. By
25 determining which of the compartments 2 has a pressure lower than that of compartment 1, and which one has a pressure higher than that of compartment 1, the compartment 2 with a pressure equal or close to that of compartment 1 can be determined, and hence the
30 concentration of the given compound in compartment 1. The pressure sensor can hereby be substituted with a simple qualitative pressure detector, only capable of detecting the direction of a pressure difference.

- 9 -

As the device can be used as an implantable device, the device may then be powered and data collected from an external device. For this purpose established techniques for biomedical telemetry can be used, e.g. inductively coupled load shift keying or LC resonance frequency modulation. The signal can also be transferred optically using infrared light, e.g. by modulation of an infrared LED or laser diode, or by imaging the inflation/deflation of flexible compartments of the implanted device according to the difference in pressure of the compartments and the external tissue and fluids.

Claims

- 5 1. Device containing at least two compartments, one of
them at least partially defined to the exterior by a
first set of barriers permeable for a set of species,
the other compartment(s) separated from said one
10 compartment by a second set of barriers permeable only
for a subset of said species, only a subset of species
that permeates into said one compartment permeates
further on into said other compartment(s).
- 15 2. Device in accordance with claim 1, characterized in
that said first set of barriers is permeable for
species up to and including the size of a specific
molecule, and said second set of barriers is permeable
for species below the size of said specific molecule.
- 20 3. Device in accordance with claim 1 or 2, characterized
in that at least one of the compartments is filled
with a solution of known concentration of solutes, all
solutes in said solution being unable to permeate
through the barriers defining said compartment.
- 25 4. Device in accordance with claim 2, characterized in
that the specific molecule is glucose.
- 30 5. Device in accordance with claim 3, characterized in
that one of the solutes in said solution is glucose.
- 35 6. Device in accordance with claim 1, characterized in
that the device is implantable and has an outer
surface, which is predominately biocompatible.

- 11 -

7. Device in accordance with claim 1, characterized in that the device further contains pressure-sensing means capable of sensing the pressures in said compartments.

5

8. Device in accordance with claim 7, characterized in that the pressure sensing means comprises a pressure sensor for sensing the pressure exterior to said compartments.

10

9. Device in accordance with claim 7, characterized in that the pressure sensing means contains a differential pressure sensor.

- 15 10. Device in accordance with claim 7, characterized in that the pressure sensing means is at least partly formed as a deflection measurement of a flexible compartment, which will increase or decrease in volume when the pressure in the compartment increases or
20 decreases.

THIS PAGE BLANK (USPTO)

1/3




FIG 1




FIG 2




FIG 3

THIS PAGE BLANK (USPTO)

2/3




FIG 4





FIG 5

THIS PAGE BLANK (USPTO)

3/3



THIS PAGE BLANK (USPTO)

INTERNATIONAL SEARCH REPORT

International Application No

PCT/DK 03/00036

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61B5/145 G01N7/10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61B A61K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, MEDLINE, BIOSIS, INSPEC

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	W0 01 35928 A (MICROCHIPS INC) 25 May 2001 (2001-05-25) page 7, line 3-19 page 9, line 30 -page 10, line 25 abstract; figure 2D	1,3,6
A	---	2,4,5, 7-10
	-/--	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

22 April 2003

Date of mailing of the international search report

16.05.2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

PÄR MORITZ/JA A

INTERNATIONAL SEARCH REPORT

International Application No

PC1/DK 03/00036

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 01 64344 A (MICROCHIPS INC) 7 September 2001 (2001-09-07) page 3, line 20-28 page 4, line 25-27 page 6 -page 8 page 10, line 4-23 page 20, line 26 -page 21, line 3 page 22, line 30 -page 24, line 30 abstract; claim 12; figures 2A-D,12D	1,3,6
A	---	2,4,5, 7-10
A	US 6 268 161 B1 (BAE YOU HAN ET AL) 31 July 2001 (2001-07-31) abstract; figure 3	1-10
A	---	
A	US 5 388 449 A (LEVEEN HARRY H ET AL) 14 February 1995 (1995-02-14) abstract	1-10
A	---	
A	WO 02 04918 A (GOVERNMENT OF THE UNITED STATE) 17 January 2002 (2002-01-17) abstract; figures 1-3	1-10
A	---	
A	US 5 337 747 A (NEFTEL FREDERIC) 16 August 1994 (1994-08-16) the whole document	1-10
A	---	
A	US 4 538 616 A (ROGOFF ROBERT) 3 September 1985 (1985-09-03) abstract; figures 1-3	1-10

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/DK 03/00036

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0135928	A	25-05-2001	AU 1616201 A	30-05-2001
			EP 1229901 A1	14-08-2002
			WO 0135928 A1	25-05-2001
			US 2002173745 A1	21-11-2002
			US 6491666 B1	10-12-2002
WO 0164344	A	07-09-2001	AU 5289001 A	12-09-2001
			EP 1261427 A2	04-12-2002
			WO 0164344 A2	07-09-2001
US 6268161	B1	31-07-2001	US 2002155425 A1	24-10-2002
			US 6475750 B1	05-11-2002
			US 2002006634 A1	17-01-2002
			US 2002042065 A1	11-04-2002
			AU 9599498 A	23-04-1999
			EP 1029229 A1	23-08-2000
			WO 9917095 A1	08-04-1999
US 5388449	A	14-02-1995	NONE	
WO 0204918	A	17-01-2002	AU 8290401 A	21-01-2002
			WO 0204918 A2	17-01-2002
US 5337747	A	16-08-1994	FR 2652736 A1	12-04-1991
			AT 119006 T	15-03-1995
			AU 638067 B2	17-06-1993
			AU 6510090 A	28-04-1991
			CA 2044150 A1	07-04-1991
			DE 69017428 D1	06-04-1995
			DE 69017428 T2	21-09-1995
			DK 451233 T3	28-08-1995
			WO 9104704 A1	18-04-1991
			EP 0451233 A1	16-10-1991
			ES 2071115 T3	16-06-1995
US 4538616	A	03-09-1985	NONE	

THIS PAGE BLANK (USPTO)

1/3




FIG 1




FIG 2




FIG 3

THIS PAGE BLANK (USPTO)

2/3




FIG 4





FIG 5

THIS PAGE BLANK (USPTO)

3/3

FIG 6



THIS PAGE BLANK (USPTO)